본문 바로가기
KERD
논문KCI 등재

Cost-Effectiveness Analysis of Glimepiride or Pioglitazone in Combination with Metformin in Type-2 Diabetic Patients

오정미|이영숙|손현순|신현택|임경화
한국임상약학회 (Korean College Of Clinical Pharmacy)|2009.12|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제19권 제2호|pp. 96-104

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Cost-Effectiveness Analysis (CEA)Cost-Effectiveness Ratio (CER)
주제분류약학

초록

배경: 당뇨병 환자에게 관상동맥심질환은 생존률, 건강 상태 유지 및 삶의 질에 주요한 영향을 미치는 합병증이며 적극적인 당뇨병 치료는 이러한 심혈관 합병증을 예방할 수 있으나 당뇨병의 적극적 치료와 관리에는 많은 비용이 소요된다. 목적: 제2형 당뇨병 환자를 대상으로 메트포르민과 글리메피리드 병합요법과 메트포르민과 피오글리타존 병합요법의 비용-효과성을 비교하고자 하였다. 연구방법: 마르코프 코호트 프로세스(Markov Cohort Process Model) 모형을 이용하여 비용-효과분석을 실시하였다. 연장된 수명 (life years gained, LYG)과 삶의 질(quality)을 보정하여 증가된 QALYs를 주요 효과 지표로 측정하였고, 총비용으로는 직접의료비용과, 환자와 가족의 교통비를 직접비의료비용으로 고려하였고 환자와 가족의 시간비용을 간접비용으로 포함하였다. 연구결과: 비용-효과분석 결과, 메트포르민과 글리메피리드 병합요법의 경우 총 비용은 5,962,288원, 효과는 7.94LYG, 6.43QALY이었다. 반면 메트포르민과 피오글리타존 병합요법은 총 비용 10,982,243원, 효과 8.62LYG, 6.99QALY으로, 점증적 비용-효과비(ICER)는 7,402,663원/LYG과 8,934,546원/QALY 이었다. 결론: 우리 사회의 연장된 수명(LYG)에 따른 지불의사가 700만원 이하인 경우는 메트포르민과 글리메피리드 병합요법이 비용-효과적인 대안이며 700만원 이상인 경우에는 메트포르민과 피오글리타존 병합요법이 비용-효과적인 대안이 될 수 있다.

참고문헌 (52)

  1. Korean Diabetes Association, "Health Insurance Review & Assessment Service. Diabetes in Korea. 1st ed", pp.7~73 (2007), Health Insurance Review & Assessment Service
  2. Ole-Petter R. Hamnvik, "Glycemic targets for patients with type 2 diabetes mellitus", Mount Sinai Journal of Medicine, 76, pp.227~233 (2009)
  3. Molyneaux LM, "Better glycemic control and risk reduction of diabetic complications in type 2 diabetes: complication with the DCCT", Diabetes Res Clin Pract, 42, pp.77~83 (1998)
  4. Turnur RC, "Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS23)", BMJ, 316, pp.823~828 (1998)
  5. UK Prospective Diabetes Study Group, "Intensive bloodglucose control with sulphonylurease or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
  6. UK Prospective Diabetes Study Group, "Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34)", Lancet, 352, pp.854~865 (1998)
  7. UK Prospective Diabetes Study Group, "Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)", Diabetes Care, 22, pp.1125~1136 (1999)
  8. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)", BMJ, 317, pp.703~713 (1998)
  9. Gray A, "Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41)", BMJ, 320, pp.1373~1378 (2000)
  10. Clarke P, "Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS 51)", Diabetologia, 44, pp.298~304 (2001)
  11. Clarke P, "Estimating utility values for health states of type 2 diabetic patients using the EQ-5D(UKPDS 62)", Med Decis Making, 22, pp.340~349 (2002)
  12. David C. Goff, Jr., "Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial", Am J Cardiol, 99, pp.4i~20i (2007)
  13. Cugnet-Anceau C, "Glycaemic control and cardiovascular morbid-mortality: the contribution of the 2008 studies", 70, pp.48~54 (2009)
  14. Beckman JA, "Diabetes and atherosclerosis", JAMA, 287, pp.2670~2681 (2002)
  15. Harris MI, "CHD mortality in diabetics and non-diabetics: NHANES results", Cardiology Rev, 17, pp.22~28 (2000)
  16. Muggeo M, "Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study", Diabetologia, 38, pp.672~679 (1995)
  17. McGovern PG, "Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997", The Minnesota Heart Survey Circulation, 104, pp.19~24 (2001)
  18. Klein R, "Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy XV; The long-term incidence of macular edema", Ophthalmology, 102, pp.7~16 (1995)
  19. Moss SE, "Long-term incidence of lower-extremity amputations in a diabetic population", Arch Fam Med, 5, pp.391~398 (1996)
  20. Wannamthee SG, "Cardiovascular disease incidence and mortality in older men with diabetes and in men coronary heart disease", Heart, 통권 : 90, pp.1398~1403 (2004)
  21. Haffner SM, "Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without prior myocardial infarction", N Engl J Med, 339, pp.229~234 (1998)
  22. Golbourt U, "Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years", World review of nutrition and dietetics, 80, pp.229~239 (1997)
  23. Verschurn, WMM, "Total cholesterol in relation to 25-year CHD and total mortality in seven countries study", Acta cardiol, 49, pp.316~318 (1994)
  24. Vivian EM, "Pharmacological management of diabetic nephropathy", Clin Ther, 24, pp.1741~1756 (2002)
  25. Hadden DR, "Macrovcular disease and hyperglycaemia:10 year survival analysis in type 2 diabetes mellitus: the Belfast diet study", Diabetic Medicine, 14, pp.663~672 (1997)
  26. Bagust A, "An economic model of the long-term health care burden of type II diabetes", Diabetologia, 44, pp.2140~2155 (2001)
  27. Bagust A, "A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies", Pharmacoeconomics, 24(1), pp.5~19 (2006)
  28. Coyle D, "Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada", Pharmacoeconomics, 20, pp.31~42 (2002)
  29. Ramsdell JW, "Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus", Pharmacoeconomics, 21, pp.819~837 (2003)
  30. Brown JB, "The global diabetes model: user friendly version 3.0", Diabetes Res Clin Pract, 50, pp.15~46 (2000)
  31. Neeser K, "Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from German statutory healthcare perspective", Pharmacoeconomics, 22, pp.321~341 (2004)
  32. Eastman RC, "Model of complications of NIDDM", Diabetes Care, 20, pp.725~734 (1997)
  33. Beale S, "Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK", Pharmacoeconomics, 21, pp.21~34 (2006)
  34. Bagust A, "Modeling EuroQol health-related utility values for diabetic complications from CODE-2 data", Health Econ, 14, pp.217~230 (2005)
  35. Veenstra DL, "A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment", Pharmacoeconomics, 20, pp.21~30 (2002)
  36. Homes J, "Health-related quality of life in type 2 diabetes", Value in Health, 3, pp.47~51 (2000)
  37. Cicero AFG, "Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by metabolic syndrome: a 12-month, double-blind, randomized clinical trial", Clin Ther, 27, pp.1383~1391 (2005)
  38. Derosa G, "Different effect of glimepiride and rosiglitazone on metabolic control type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes, Obesity and Metabolism", 8, pp.197~205 (2006)
  39. Umpierrez G, "Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy : results of a randomized clinical trial", Curr Med Res Opin, 22, pp.751~759 (2006)
  40. Derosa G, "Metforminpioglitazone and metformin-rosiglitazone effects on nonconventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome", J Clin Pharm Ther, 31, pp.375~383 (2006)
  41. Derosa G, "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin", Intern Med J, 37, pp.79~86 (2007)
  42. Matthews DR, "Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliglazide to metformin in patients with type 2 diabetes: a randomized, comparative study", Diabetes Metab Res Rev, 21, pp.167~174 (2005)
  43. Derosa G, "Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial", Diabetes Obes Metab, 8, pp.197~205 (2006)
  44. Stevens RJ, "The UKPDS risk engine : a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)", Clin Sci, 101, pp.671~679 (2001)
  45. Anderson KM, "Cardiovascular disease risk profiles", Am Heart J, 121, pp.293~298 (1990)
  46. National Health Insurance Corporation, "The healthinsurance annual statistical report" (2008)
  47. The co-payment realities survey data in the patients with national health insurance, "National Health Insurance Corporation", ~ (2007)
  48. Allowance-item pharmaceutical-price file and weighted average price, "Health Insurance Review Agency", ~ (2008)
  49. The data of national health insurance care-benefit cost, "Ministry Institute for Health Welfare and Family Affairs, Health Insurance Review Agency", ~ (2008)
  50. National Health and Nutrition Survey, "Korea Institute for Health and Social Affairs", ~ (2001)
  51. National Health Realities Survey data, "Korea Institute for Health and Social Affairs", ~ (2000)
  52. Monthly Labor Statistics, "Labor Statistics of Korea", ~ (2008)

관련 논문AI추천

국민건강보험공단 제2형 당뇨 건강검진사업의 비용-효과분석권혜영, 김유정, 이애경, 정현진, 한준태한국보건경제정책학회 · 보건경제와 정책연구2008 · 제14권 제1호제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구곽혜선, 김재연, 박지혜, 이병구한국임상약학회 · 한국임상약학회지2014 · 제24권 제3호선택약가제도가 건강보험 약품비 지출에 미치는 영향: 경구용 당뇨병 치료제를 대상으로 한 시나리오 분석김남효, 손현순, 신인철, 신현택, 최경업한국임상약학회 · 한국임상약학회지2014 · 제24권 제2호제1형 당뇨병에서 연속혈당측정기 사용의 비용효과성의 체계적 문헌고찰김희선, 박종연, 장나라한국보건의료기술평가학회 · 보건의료기술평가2020 · 제8권 제1호Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus고승현, 김난희, 김진화, 김현진, 문민경, 박석오, 이병완, 이상열, 최경묵, 허규연, the Committee of Clinical Practice Guideline of KDA대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제6호지역병원 외래환자의 경구용 당뇨약제의 처방분석권호엽, 김라영, 박선영, 박형건, 신억섭, 이경희, 이현태한국병원약사회 · 병원약사회지2007 · 제24권 제1호

이 간행물의 다른 논문 (11건)

난소제거 흰쥐에서 단삼과 키토산 혼합물의 골다공증 개선효과김도성, 이용철, 류완희, 김형룡, 한송희, 채한정, 박성주pp. 75-80경제성평가의 국가간 적용가능성 진단도구를 이용한 류마티스관절염 치료제 사례 연구이의경, 강숙현, 구혜민, 권정미, 박세영pp. 81-88Gemtuzumab ozogamicin과 항체공학김은영pp. 89-95입원환자의 경구용 levofloxacin 약물 사용 평가김원규, 박윤희, 노은숙, 방은미, 임금숙pp. 105-109복약지도 만족도가 복약순응도에 미치는 영향 : 외래환자를 대상으로김수진, 김주혁, 허순임, 허재헌pp. 110-119
원문 보기